PlumX Metrics
Embed PlumX Metrics

Detection of early onset carnitine palmitoyltransferase ii deficiency by newborn screening. Should cpt ii deficiency be a primary disease target?

International Journal of Neonatal Screening, ISSN: 2409-515X, Vol: 7, Issue: 3
2021
  • 4
    Citations
  • 0
    Usage
  • 16
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Early‐onset carnitine palmitoyltransferase II deficiency (CPT II deficiency) (OMIM 600650) can result in severe outcomes, which are often fatal in the neonatal to infantile period. CPT II deficiency is a primary target in the Maritime Newborn Screening Program. We report a case of neona-tal‐onset CPT II deficiency identified through expanded newborn screening with tandem mass spec-trometry. Identification through newborn screening led to early treatment interventions, avoidance of metabolic decompensation, and a better clinical outcome. Newborn screening for CPT II deficiency is highly sensitive and specific with no false positives identified. The only screen positive case detected identified a true positive case. This experience illustrates the importance of newborn screening for CPT II deficiency and demonstrates why reconsideration should be taken to add this disease as a primary newborn screening target.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know